Data / Drug companies / Ticagrelor
Ticagrelor: 32 companies and 57 products in the FDA NDC directory
Ticagrelor is listed in the FDA National Drug Code Directory by 32 companies, with 57 products in commercial distribution. 53 of the products (93.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; tablet, film coated, and the newest product started marketing on November 1, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 32
- Products
- 57
- Generic (ANDA) products
- 53 (93.0%)
- Application numbers
- 20
- Routes
- Oral
- Brand names
- Brilinta
- openFDA record search
- api.fda.gov
Companies that list ticagrelor
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Aphena Pharma Solutions - Tennessee, LLC | 3 | tablet; tablet, film coated | Generic drugs (ANDA) | May 7, 2025 |
| AiPing Pharmaceutical, Inc. | 2 | tablet | Generic drugs (ANDA) | June 10, 2026 |
| Alembic Pharmaceuticals Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | October 28, 2025 |
| Alembic Pharmaceuticals Limited | 2 | tablet, film coated | Generic drugs (ANDA) | October 28, 2025 |
| American Health Packaging | 2 | tablet | Generic drugs (ANDA) | February 18, 2026 |
| Apotex Corp. | 2 | tablet | Generic drugs (ANDA) | October 31, 2025 |
| Ascend Laboratories, LLC | 2 | tablet; tablet, film coated | Generic drugs (ANDA) | October 28, 2025 |
| AstraZeneca Pharmaceuticals LP | 2 | tablet | New drug applications (NDA) | September 4, 2015 |
| AvKARE | 2 | tablet | Generic drugs (ANDA) | October 9, 2025 |
| Bionpharma Inc. | 2 | tablet | Generic drugs (ANDA) | October 28, 2025 |
| Changzhou Pharmaceutical Factory | 2 | tablet | Generic drugs (ANDA) | October 28, 2025 |
| Cipla USA Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | October 29, 2025 |
| Dr. Reddy's Laboratories Inc. | 2 | tablet | Generic drugs (ANDA) | October 28, 2025 |
| Exelan Pharmaceuticals Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | October 29, 2025 |
| Laurus Labs Limited | 2 | tablet | Generic drugs (ANDA) | August 20, 2026 |
| Lifestar Pharma LLC | 2 | tablet, film coated | Generic drugs (ANDA) | February 6, 2026 |
| Macleods Pharmaceuticals Limited | 2 | tablet, film coated | Generic drugs (ANDA) | October 28, 2025 |
| Mylan Pharmaceuticals Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | September 25, 2025 |
| NorthStar RxLLC | 2 | tablet, film coated | Generic drugs (ANDA) | August 10, 2026 |
| Novadoz Pharmaceuticals LLC | 2 | tablet | Generic drugs (ANDA) | July 19, 2025 |
| Oryza Pharmaceuticals Inc. | 2 | tablet | Generic drugs (ANDA) | December 1, 2025 |
| Radha Pharmaceuticals, Inc. | 2 | tablet | Generic drugs (ANDA) | October 9, 2025 |
| ScieGen Pharmaceuticals, Inc. | 2 | tablet | Generic drugs (ANDA) | October 9, 2025 |
| Teva Pharmaceuticals, Inc. | 2 | tablet, film coated | Generic drugs (ANDA) | May 1, 2025 |
| Aphena Pharma Solutions - Tennessee, LLC | 1 | tablet | Generic drugs (ANDA) | April 24, 2025 |
| AvPAK | 1 | tablet | Generic drugs (ANDA) | October 29, 2025 |
| Cardinal Health 107, LLC | 1 | tablet | New drug applications (NDA) | August 5, 2011 |
| Golden State Medical Supply, Inc. | 1 | tablet | Generic drugs (ANDA) | May 1, 2025 |
| Hisun Pharmaceuticals USA, Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | May 1, 2025 |
| Micro Labs Limited | 1 | tablet, film coated | Generic drugs (ANDA) | November 1, 2026 |
| Redpharm Drug | 1 | tablet, film coated | Generic drugs (ANDA) | May 1, 2025 |
| Solco Healthcare US, LLC | 1 | tablet, film coated | Generic drugs (ANDA) | April 1, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 33 | 57.9% |
| Tablet, film coated | 24 | 42.1% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 53 | 93% |
| New drug applications (NDA) | 4 | 7% |
Pharmacologic classes
| Class | Products |
|---|---|
| P2Y12 Platelet Inhibitor | 57 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.